ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Alternative Realities: Investing in the Future of Healthcare"
Episode Synopsis
Season 01 Episode 06
On previous episodes, we’ve discussed the muted return outlook for a traditional 60/40 portfolio and the return-enhancing potential of Private Equity and Venture Capital. As companies wait longer to IPO, investors are turning to private markets for access to the fastest-growing part of a business’s lifecycle. In this episode, we’re going to explore the opportunities in private healthcare and biotechnology. Dr. David Kelly is joined by Gaurav Gupta, Managing Partner of Life Science Private Capital within J.P. Morgan Private Capital. He is a neurosurgeon turned investor, and we’re so excited to have him here to discuss the trends he’s seeing in the market.
On previous episodes, we’ve discussed the muted return outlook for a traditional 60/40 portfolio and the return-enhancing potential of Private Equity and Venture Capital. As companies wait longer to IPO, investors are turning to private markets for access to the fastest-growing part of a business’s lifecycle. In this episode, we’re going to explore the opportunities in private healthcare and biotechnology. Dr. David Kelly is joined by Gaurav Gupta, Managing Partner of Life Science Private Capital within J.P. Morgan Private Capital. He is a neurosurgeon turned investor, and we’re so excited to have him here to discuss the trends he’s seeing in the market.
More episodes of the podcast Insights Now
Quantitative Investing Explained
17/10/2025
Rethinking Retirement Through Research
10/10/2025
How Can Policy Power Portfolios?
09/10/2025
Why Is Asset Allocation So Important?
31/08/2025
In God we trust